Institution
Tongji University
Education•Shanghai, China•
About: Tongji University is a education organization based out in Shanghai, China. It is known for research contribution in the topics: Population & Adsorption. The organization has 76116 authors who have published 81176 publications receiving 1248911 citations. The organization is also known as: Tongji & Tóngjì Dàxué.
Topics: Population, Adsorption, Cancer, Finite element method, Lung cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, a new plastic-damage constitutive model for concrete is proposed, where a tensile and a shear damage variable are adopted to describe the degradation of the macromechanical properties of concrete.
459 citations
••
TL;DR: In this article, the authors performed genome-wide mapping of epigenetically marked nucleosomes to determine their position both near transcription start sites and at distal regulatory elements, including enhancers.
Abstract: Chromatin plays a central role in eukaryotic gene regulation. We performed genome-wide mapping of epigenetically marked nucleosomes to determine their position both near transcription start sites and at distal regulatory elements, including enhancers. In prostate cancer cells, where androgen receptor binds primarily to enhancers, we found that androgen treatment dismisses a central nucleosome present at androgen receptor binding sites that is flanked by a pair of marked nucleosomes. A new quantitative model built on the behavior of such nucleosome pairs correctly identified regions bound by the regulators of the immediate androgen response, including androgen receptor and FOXA1. More importantly, this model also correctly predicted previously unidentified binding sites for other transcription factors present after prolonged androgen stimulation, including OCT1 and NKX3-1. Therefore, quantitative modeling of enhancer structure provides a powerful predictive method to infer the identity of transcription factors involved in cellular responses to specific stimuli.
459 citations
••
TL;DR: Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lung cancer and these results suggest a reduced risk of CNS progression with osimert inib versus standard EGFR -TKIs.
Abstract: Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly assigned to osimertinib or standard EGFR-TKIs (gefitinib or erlotinib); brain scans were not mandated unless clinically indicated. Patients with asymptomatic or stable CNS metastases were included. In patients with symptomatic CNS metastases, neurologic status was required to be stable for ≥ 2 weeks after completion of definitive therapy and corticosteroids. A preplanned subgroup analysis with CNS progression-free survival as primary objective was conducted in patients with measurable and/or nonmeasurable CNS lesions on baseline brain scan by blinded independent central neuroradiologic review. The CNS evaluable-for-response set included patients with ≥ one measurable CNS lesion. Results Of 200 patients with available brain scans at baseline, 128 (osimertinib, n = 61; standard EGFR-TKIs, n = 67) had measurable and/or nonmeasurable CNS lesions, including 41 patients (osimertinib, n = 22; standard EGFR-TKIs, n = 19) with ≥ one measurable CNS lesion. Median CNS progression-free survival in patients with measurable and/or nonmeasurable CNS lesions was not reached with osimertinib (95% CI, 16.5 months to not calculable) and 13.9 months (95% CI, 8.3 months to not calculable) with standard EGFR-TKIs (hazard ratio, 0.48; 95% CI, 0.26 to 0.86; P = .014 [nominally statistically significant]). CNS objective response rates were 91% and 68% in patients with ≥ one measurable CNS lesion (odds ratio, 4.6; 95% CI, 0.9 to 34.9; P = .066) and 66% and 43% in patients with measurable and/or nonmeasurable CNS lesions (odds ratio, 2.5; 95% CI, 1.2 to 5.2; P = .011) treated with osimertinib and standard EGFR-TKIs, respectively. Probability of experiencing a CNS progression event was consistently lower with osimertinib versus standard EGFR-TKIs. Conclusion Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lung cancer. These results suggest a reduced risk of CNS progression with osimertinib versus standard EGFR-TKIs.
459 citations
••
TL;DR: In this paper, a review of the research progress on conducting polymers and their corresponding thermoelectric (TE) nanocomposites is presented, focusing on the polymeric and polymer-inorganic TE nanocomposition materials.
455 citations
••
TL;DR: The IMpower010 trial as mentioned in this paper evaluated adjuvant atezolizumab versus best supportive care (observation and regular scans for disease recurrence) in patients with early-stage non-small-cell lung cancer.
450 citations
Authors
Showing all 76610 results
Name | H-index | Papers | Citations |
---|---|---|---|
Gang Chen | 167 | 3372 | 149819 |
Yang Yang | 164 | 2704 | 144071 |
Georgios B. Giannakis | 137 | 1321 | 73517 |
Jian Li | 133 | 2863 | 87131 |
Jianlin Shi | 127 | 859 | 54862 |
Zhenyu Zhang | 118 | 1167 | 64887 |
Ju Li | 109 | 623 | 46004 |
Peng Wang | 108 | 1672 | 54529 |
Qian Wang | 108 | 2148 | 65557 |
Yan Zhang | 107 | 2410 | 57758 |
Richard B. Kaner | 106 | 557 | 66862 |
Han-Qing Yu | 105 | 718 | 39735 |
Wei Zhang | 104 | 2911 | 64923 |
Fabio Marchesoni | 104 | 607 | 74687 |
Feng Li | 104 | 995 | 60692 |